0001209191-23-009237.txt : 20230214
0001209191-23-009237.hdr.sgml : 20230214
20230214171220
ACCESSION NUMBER: 0001209191-23-009237
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230210
FILED AS OF DATE: 20230214
DATE AS OF CHANGE: 20230214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tatsis Ourania
CENTRAL INDEX KEY: 0001789815
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 23631506
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS, INC.
STREET 2: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-10
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001789815
Tatsis Ourania
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, Chief Reg. & Quality Off.
Common Stock
2023-02-10
4
F
0
1377
294.33
D
69035
D
Common Stock
2023-02-13
4
F
0
2995
298.26
D
66040
D
Common Stock
2023-02-13
4
S
0
2
295.84
D
66038
D
Common Stock
2023-02-13
4
S
0
78
298.11
D
65960
D
Common Stock
2023-02-13
4
S
0
120
298.98
D
65840
D
Common Stock
2023-02-13
4
S
0
64
299.88
D
65776
D
Common Stock
2023-02-13
4
S
0
11
300.79
D
65765
D
Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1.
Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $298.11 (range $297.51 to $298.50).
Open market sales reported on this line occurred at a weighted average price of $298.98 (range $298.53 to $299.50).
Open market sales reported on this line occurred at a weighted average price of $299.88 (range $299.62 to $300.53).
/s/ Christiana Stevenson, Attorney-in-Fact
2023-02-14